[1] A KASSAM. Identification of anovulation and transient luteal function using a urinary pregnanediol-3-glucuronide ratio algorithm.[J]. Environmental Health Perspectives, 1996, 104 4: 408-413. DOI:
10.1289/ehp.96104408[2] WIEBE J P. Progesterone metabolites in breast cancer.[J]. Endocrine-related cancer, 2006, 13 3: 717-738. DOI:
10.1677/erc.1.01010[3] KATHLEEN A O’CONNOR. Urinary estrone conjugate and pregnanediol 3-glucuronide enzyme immunoassays for population research.[J]. Clinical chemistry, 2003, 49 7: 1139-1148. DOI:
10.1373/49.7.1139[4] C J MUNRO. Relationship of serum estradiol and progesterone concentrations to the excretion profiles of their major urinary metabolites as measured by enzyme immunoassay and radioimmunoassay.[J]. Clinical chemistry, 1991, 37 6: 838-844.
[5] JELENA M PAVLOVI. Sex hormones in women with and without migraine: Evidence of migraine-specific hormone profiles.[J]. Neurology, 2016, 87 1: 49-56. DOI:
10.1212/wnl.0000000000002798[6] ANNEKATRIN LUKANOVA Rudolf K. Endogenous hormones and ovarian cancer: epidemiology and current hypotheses.[J]. Cancer Epidemiology Biomarkers & Prevention, 2005, 14 1: 98-107.
[7] J JULIE KIM Serdar E B Takeshi Kurita. Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer.[J]. ACS Omega, 2013: 130-162. DOI:
10.1210/er.2012-1043